ABSTRACT
Picloram resistance exhibited by transgenic tobacco (Nicotiana tabacum) plants expressing an anti-picloram single-chain variable fragment (scFv) antibody was investigated through the study of homozygous lines expressing the antibody. Dose-response bioassays, using foliar application of picloram, showed that these homozygous transgenic plants were resistant to at least 5 g of ai ha-1 picloram and grew normally to produce seed, whereas wild-type plants did not survive. Although these lines had improved resistance compared with those previously reported, significant improvements are still required to achieve field-level resistance. Uptake and translocation studies demonstrated that [14C]picloram translocation from treated leaves to the apical meristem was reduced in transgenic versus wild-type plants. The presence of [14C]picloram visualized by autoradiography and quantified by liquid scintillation spectrometry, demonstrated the distribution of more picloram in the treated leaf and less in the apical meristem of transgenic plants when compared to wild-type plants. No differences between transgenic and wild-type plants were found in the distribution of [14C]clopyralid, a herbicide with structural similarity to picloram as well as the same mechanism of action. No differences were found in the metabolism of [14C]picloram. Taken together, these results suggest that reduced translocation to the site of action is a major mechanism responsible for picloram resistance in tobacco plants expressing this anti-picloram antibody.
Subject(s)
Herbicide Resistance , Immunoglobulin Variable Region/immunology , Nicotiana/metabolism , Picloram/immunology , Picloram/metabolism , Antibodies/genetics , Antibodies/immunology , Gene Expression , Herbicides/immunology , Herbicides/metabolism , Herbicides/pharmacology , Immunoglobulin Variable Region/genetics , Meristem/metabolism , Picloram/pharmacology , Plant Leaves/metabolism , Plants, Genetically Modified/immunology , Plants, Genetically Modified/metabolism , Nicotiana/drug effects , Nicotiana/immunologyABSTRACT
Botulinum neurotoxins (BoNTs) are the most poisonous substances known and are thus classified as high-risk threats for use as bioterror agents. To examine the potential of transgenic plants as bioreactors for the production of BoNT antidotes, we transformed tobacco with an optimized, synthetic gene encoding a botulinum neurotoxin A (BoNT/A) neutralizing single-chain Fv (scFv) recombinant antibody fragment. In vitro mouse muscle twitch assays demonstrated the functional utility of this scFv extracted from tobacco for neutralizing the paralytic effects of BoNT/A at neuromuscular junctions. Based on the efficiency of the scFv capture process and the dose required to antidote a human being, 1-2 ha of this tobacco could yield up to 4 kg of scFv, which would be enough to contribute to the manufacture of 1,000,000 therapeutic doses of a monoclonal antibody (mAb) cocktail capable of neutralizing the effects of BoNT poisoning. Transgenic plants could provide an inexpensive production platform for expression of multiple mAbs toward the creation of polyclonal therapies (i.e. pooled mAbs) as the next improvement in recombinant antibody therapy.
